Tamanho do efeito da clomipramina no transtorno obsessivo-compulsivo Serie Psicofarmacologia - 71

Leonardo Fontenelle; Carla Marques; Ivan Figueira; Antônio Egídio Nardi; Márcio Versiani

Tamanho do efeito da clomipramina no transtorno obsessivo-compulsivo Serie Psicofarmacologia - 71

Translated title of the contribution: The effect-size of clomipramine in obsessive-compulsive disorder

Leonardo Fontenelle, Carla Marques, Ivan Figueira, Antônio Egídio Nardi, Márcio Versiani

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Clomipramine has been the first drug for which specific therapeutic effects in Obsessive-Compulsive Disorder (OCD) have been demonstrated in empirical, open studies, with doses of circa 200 mg/day, after three months of treatment. Double-blind placebo-controlled studies have confirmed the efficacy of clomipramine in OCD. The antiobsessive effect of clomipramine is independent of the co-occurrence of depression. The effect-size (ES) of clomipramine in OCD calculated as the proportion of responders to clomipramine divided by the proportion of responders to placebo is larger than the effect-sizes (ESs) of the selective serotonin reuptake inhibitors (SSRIs).

Translated title of the contribution	The effect-size of clomipramine in obsessive-compulsive disorder
Original language	Portuguese
Pages (from-to)	131-143
Number of pages	13
Journal	Jornal Brasileiro de Psiquiatria
Volume	47
Issue number	3
Publication status	Published - 1 Mar 1998
Externally published	Yes

Keywords

Clomipramine
Obsessive-compulsive disorder
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c89e5a7b0b6a491fb778e0f55df0105a,

title = "Tamanho do efeito da clomipramina no transtorno obsessivo-compulsivo Serie Psicofarmacologia - 71",

abstract = "Clomipramine has been the first drug for which specific therapeutic effects in Obsessive-Compulsive Disorder (OCD) have been demonstrated in empirical, open studies, with doses of circa 200 mg/day, after three months of treatment. Double-blind placebo-controlled studies have confirmed the efficacy of clomipramine in OCD. The antiobsessive effect of clomipramine is independent of the co-occurrence of depression. The effect-size (ES) of clomipramine in OCD calculated as the proportion of responders to clomipramine divided by the proportion of responders to placebo is larger than the effect-sizes (ESs) of the selective serotonin reuptake inhibitors (SSRIs).",

keywords = "Clomipramine, Obsessive-compulsive disorder, Review",

author = "Leonardo Fontenelle and Carla Marques and Ivan Figueira and Nardi, {Ant{\^o}nio Eg{\'i}dio} and M{\'a}rcio Versiani",

year = "1998",

month = mar,

day = "1",

language = "Portuguese",

volume = "47",

pages = "131--143",

journal = "Jornal Brasileiro de Psiquiatria",

issn = "0047-2085",

publisher = "Editora Cientifica Nacional Ltd. (E C N)",

number = "3",

}

TY - JOUR

T1 - Tamanho do efeito da clomipramina no transtorno obsessivo-compulsivo Serie Psicofarmacologia - 71

AU - Fontenelle, Leonardo

AU - Marques, Carla

AU - Figueira, Ivan

AU - Nardi, Antônio Egídio

AU - Versiani, Márcio

PY - 1998/3/1

Y1 - 1998/3/1

N2 - Clomipramine has been the first drug for which specific therapeutic effects in Obsessive-Compulsive Disorder (OCD) have been demonstrated in empirical, open studies, with doses of circa 200 mg/day, after three months of treatment. Double-blind placebo-controlled studies have confirmed the efficacy of clomipramine in OCD. The antiobsessive effect of clomipramine is independent of the co-occurrence of depression. The effect-size (ES) of clomipramine in OCD calculated as the proportion of responders to clomipramine divided by the proportion of responders to placebo is larger than the effect-sizes (ESs) of the selective serotonin reuptake inhibitors (SSRIs).

AB - Clomipramine has been the first drug for which specific therapeutic effects in Obsessive-Compulsive Disorder (OCD) have been demonstrated in empirical, open studies, with doses of circa 200 mg/day, after three months of treatment. Double-blind placebo-controlled studies have confirmed the efficacy of clomipramine in OCD. The antiobsessive effect of clomipramine is independent of the co-occurrence of depression. The effect-size (ES) of clomipramine in OCD calculated as the proportion of responders to clomipramine divided by the proportion of responders to placebo is larger than the effect-sizes (ESs) of the selective serotonin reuptake inhibitors (SSRIs).

KW - Clomipramine

KW - Obsessive-compulsive disorder

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=0031780761&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031780761

SN - 0047-2085

VL - 47

SP - 131

EP - 143

JO - Jornal Brasileiro de Psiquiatria

JF - Jornal Brasileiro de Psiquiatria

IS - 3

ER -

Tamanho do efeito da clomipramina no transtorno obsessivo-compulsivo Serie Psicofarmacologia - 71

Abstract

Keywords

UN SDGs

Other files and links

Cite this